These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15269190)

  • 21. Properties of the yeast nuclear histone deacetylase.
    Sanchez del Pino MM; Lopez-Rodas G; Sendra R; Tordera V
    Biochem J; 1994 Nov; 303 ( Pt 3)(Pt 3):723-9. PubMed ID: 7980438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a LC-MS assay for the quantification of ikh12 a novel anti-tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study.
    Otaegui D; Masdeu C; Aldaba E; Vara Y; Zubia A; San Sebastian E; Alcalá M; Villafruela S; Cossío FP; Rodriguez-Gascón A
    Biomed Chromatogr; 2015 Aug; 29(8):1249-58. PubMed ID: 25616154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
    Leng C; Gries M; Ziegler J; Lokshin A; Mascagni P; Lentzsch S; Mapara MY
    Exp Hematol; 2006 Jun; 34(6):776-87. PubMed ID: 16728283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of histone deacetylation by trichostatin A intensifies the transcriptions of neuronal c-fos and c-jun genes after kainate stimulation.
    Sng JC; Taniura H; Yoneda Y
    Neurosci Lett; 2005 Oct; 386(3):150-5. PubMed ID: 16002216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum.
    Kim HM; Oh SJ; Park SK; Han G; Kim K; Lee KS; Kang JS; Nam M; Lee K
    Xenobiotica; 2008 Mar; 38(3):281-93. PubMed ID: 18274957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
    Novotny-Diermayr V; Sangthongpitag K; Hu CY; Wu X; Sausgruber N; Yeo P; Greicius G; Pettersson S; Liang AL; Loh YK; Bonday Z; Goh KC; Hentze H; Hart S; Wang H; Ethirajulu K; Wood JM
    Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies.
    Yeo P; Xin L; Goh E; New LS; Zeng P; Wu X; Venkatesh P; Kantharaj E
    Biomed Chromatogr; 2007 Feb; 21(2):184-9. PubMed ID: 17221921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
    Rehni AK; Singh N; Rachamalla M; Tikoo K
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):605-19. PubMed ID: 22362134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
    Buggy JJ; Cao ZA; Bass KE; Verner E; Balasubramanian S; Liu L; Schultz BE; Young PR; Dalrymple SA
    Mol Cancer Ther; 2006 May; 5(5):1309-17. PubMed ID: 16731764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
    Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats.
    Romieu P; Host L; Gobaille S; Sandner G; Aunis D; Zwiller J
    J Neurosci; 2008 Sep; 28(38):9342-8. PubMed ID: 18799668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
    Leoni F; Zaliani A; Bertolini G; Porro G; Pagani P; Pozzi P; Donà G; Fossati G; Sozzani S; Azam T; Bufler P; Fantuzzi G; Goncharov I; Kim SH; Pomerantz BJ; Reznikov LL; Siegmund B; Dinarello CA; Mascagni P
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2995-3000. PubMed ID: 11867742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
    Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
    Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
    Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
    J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
    Jung M; Brosch G; Kölle D; Scherf H; Gerhäuser C; Loidl P
    J Med Chem; 1999 Nov; 42(22):4669-79. PubMed ID: 10579829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
    Lee JH; Park JH; Jung Y; Kim JH; Jong HS; Kim TY; Bang YJ
    Mol Cancer Ther; 2006 Dec; 5(12):3085-95. PubMed ID: 17172411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
    Gunin AG; Kapitova IN; Suslonova NV
    J Endocrinol; 2005 Jun; 185(3):539-49. PubMed ID: 15930180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.